HC Wainwright Has Bullish Estimate for INO Q2 Earnings

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – Stock analysts at HC Wainwright boosted their Q2 2026 EPS estimates for shares of Inovio Pharmaceuticals in a note issued to investors on Monday, June 1st. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will earn ($0.26) per share for the quarter, up from their prior forecast of ($0.28). HC Wainwright currently has a “Neutral” rating and a $2.50 target price on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($0.98) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($1.01) EPS, Q1 2027 earnings at ($0.18) EPS, Q2 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.03) EPS and Q4 2027 earnings at $0.07 EPS.

Several other analysts have also issued reports on INO. Oppenheimer restated an “outperform” rating on shares of Inovio Pharmaceuticals in a research note on Friday, March 13th. Wall Street Zen downgraded Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Weiss Ratings downgraded shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Inovio Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $4.25.

Inovio Pharmaceuticals Trading Down 5.5%

NASDAQ INO opened at $1.21 on Wednesday. The firm’s fifty day moving average price is $1.29 and its two-hundred day moving average price is $1.62. The firm has a market capitalization of $99.55 million, a P/E ratio of -0.83 and a beta of 1.49. Inovio Pharmaceuticals has a 1 year low of $1.03 and a 1 year high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.02.

Institutional Trading of Inovio Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Boxer Capital Management LLC bought a new stake in Inovio Pharmaceuticals in the 3rd quarter valued at $5,382,000. GSA Capital Partners LLP lifted its holdings in shares of Inovio Pharmaceuticals by 171.4% during the third quarter. GSA Capital Partners LLP now owns 443,104 shares of the biopharmaceutical company’s stock worth $1,037,000 after buying an additional 279,844 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Inovio Pharmaceuticals during the third quarter worth $41,000. Raymond James Financial Inc. boosted its position in shares of Inovio Pharmaceuticals by 4,396.0% in the third quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 16,309 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its position in shares of Inovio Pharmaceuticals by 752.9% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 18,160 shares during the period. 26.79% of the stock is owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.